Search Results

Processed Fat Cells Show Potential to Treat Refractory Ischemia in ATHENA

May 5, 2016—Patients treated with processed autologous adipose-derived regenerative cells (ADRCs) injected into the heart muscle demonstrated symptomatic improvement and a trend toward lower rates of heart failure hospitalizations and angina, despite no improvement in left ventricle ejection fraction (LVEF) or ventricular volumes.  These findings from the ATHENA trial were presented as a late-breaking clinical trial at the Society for Cardiovascular Angiography and Interventions (SCAI) 2016 scientific sessions in Orlando, Florida.

Study Identifies Delays in STEMI Patients Receiving Emergency PCI

September 19, 2011―The American Heart Association (AHA) announced the publication of a study that showed that despite improvements in treating heart attack patients needing emergency angioplasty procedures, delays still occur, particularly in transferring patients to hospitals that can perform the procedure.

Stem Cell Therapy Shows Potential for Challenging Refractory Angina Patients

May 5, 2016—The Society for Cardiovascular Angiography and Interventions (SCAI) announced that results from the RENEW study of stem cell therapy to treat patients with challenging refractory angina (RA) demonstrated promising results, including improved exercise time, reduced angina, and reduced mortality.

SCAI Cancels 2020 Scientific Sessions and Establishes COVID-19 Resource Center

March 23, 2020—Ehtisham Mahmud, MD, the 2019–20 President of the Society for Cardiovascular Angiography and Interventions (SCAI), announced the cancellation of the SCAI 2020 Scientific Sessions which were scheduled to take place May 13–16 in Atlanta, Georgia.

Complete Revascularization Shown to Improve Outcomes for CAD Patients

April 25, 2010—The Society for Cardiovascular Angiography and Interventions announced that a 3-year, retrospective study conducted at the University of Minnesota's Minneapolis Heart Institute Foundation determined that 28.8% of patients with significant coronary artery disease (CAD) who did not undergo complete revascularization had a higher mortality rate than patients who were completely revascularized.

Risk of Cataracts Studied in Interventional Cardiologists and Catheterization Lab Staff

July 31, 2017—In Catheterization and Cardiovascular Interventions, Ahmed Elmaraezy, MD, et al published a systematic review and meta-analysis that assessed the risk of developing a radiation-induced cataract among interventional cardiologists and catheterization lab staff (2017;90:1–9).

Sunil V. Rao, MD, Named 2022-2023 President of SCAI

May 24, 2022—Sunil V. Rao, MD, FSCAI was recently named the 2022-2023 President of the Society for Cardiovascular Angiography & Interventions (SCAI). His appointment was announced at SCAI’s 2022 Scientific Sessions held May 19-22 in Atlanta, Georgia.

XyloCor and SmartCella Sign Licensing Agreement for Catheter-Delivered Gene Therapy to the Heart

July 15, 2024—XyloCor Therapeutics, Inc., a clinical stage biopharmaceutical company developing novel gene therapies for cardiovascular disease, and SmartWise, a unit of SmartCella Holding AB, recently announced they have entered into a licensing agreement under which XyloCor has rights to the SmartWise’s Extroducer infusion catheter system.

NACMI Registry Shows Lower In-Hospital Mortality for STEMI Patients with COVID-19 in 2021

April 4, 2022—The Society for Cardiovascular Angiography & Interventions (SCAI) announced that new findings showed a 25% reduction in early mortality in year 2021 compared to 2020 among patients with ST-segment elevation myocardial infarction (STEMI) and COVID-19 infection and zero deaths for patients vaccinated against SARS-CoV-2.

SCAI Releases Updated Expert Consensus on Shock Classification

January 31, 2022—The Society for Cardiovascular Angiography and Interventions (SCAI) announced the release of an expert consensus statement updating the SCAI shock classification that was first released in 2019.